Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

FLT3 overexpression is a recurrent event in various acute leukaemia subtypes. This transcriptional deregulation is important to define the prognostic risk for many patients. Of note, the molecular mechanisms leading to this gene upregulation are unknown for a substantial number of cases. In this Mini-Review, we highlight the role of FLT3 overexpression in acute leukaemia and discuss emerging mechanisms accounting for this upregulation. The benefits of using targeted therapy are also addressed in the overexpression context, posing other therapeutic possibilities based on state-of-the-art knowledge that could be considered for future research.

Original publication

DOI

10.1016/j.bbcan.2019.06.001

Type

Journal article

Journal

Biochimica et biophysica acta. Reviews on cancer

Publisher

Elsevier BV

Publication Date

01/08/2019

Volume

1872

Pages

80 - 88

Keywords

Gene Expression Regulation, Neoplastic, Prognosis, Humans, Mutation, fms-Like Tyrosine Kinase 3, Leukemia, Myeloid, Acute